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Background: Previous studies with cystic fibrosis transmembrane conductance regulator (CFTR) DF508 mice indicate that estrogen levels
may play a role in the occurrence or severity of CF-associated liver disease. However, the underlying mechanisms of liver disease in CF are
poorly understood.
Methods: The levels of SULT1E1 (estrogen sulfotransferase) were measured in livers of control and CFTR-knockout (KO) mice. The
impact of increased SULT1E1 activity on hepatic protein expression was assessed by immunoblot and MALDI mass spectrometric analysis.
Results: SULT1E1 expression was significantly elevated in livers of several CFTR-KO mice. SULT1E1 and CFTR were specifically
detected in hepatocytes and cholangiocytes, respectively. Elevated SULT1E1 activity may result in lower levels of free h-estradiol thereby
altering estrogen-responsive hepatic protein expression. Estrogen receptors (ER)-a and h were differentially regulated in CFTR-KO and
CFTR-DF508 mice. ERa expression was reduced in mice with high SULT1E1 activity. Glutathione S-transferase-P1 and carbonic anhydrase
III were significantly decreased in CFTR (/) mice with high SULT1E1 activity. Furthermore, cytochrome P450 2B9, also estrogen
regulated, was significantly induced in the livers of CFTR (/) mice with high SULT1E1 activity.
Conclusions: Elevated SULT1E1 levels and associated alterations in estrogen-regulated hepatic protein expression may play an important
role in CF liver disease.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Sulfotransferase; h-estradiol; Cystic fibrosis transmembrane conductance regulator; CF-liver disease1. Introduction
Cystic fibrosis (CF) is the most common lethal inherited
disorder in Caucasians and affects many organs including
the lungs, intestine, pancreas and livers [1,2]. Whereas,
morbidity and mortality in CF are primarily related to
pulmonary disease, liver disease is becoming more preva-
lent as improved treatment results in an aging adult CF
population. Liver disease is now considered the leading1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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pulmonary disease [3,4]. Although the pathogenesis of
CF-associated liver disease is not fully understood, the
impaired secretory function of the biliary epithelium
resulting from the defective cystic fibrosis transmembrane
conductance regulator (CFTR) is thought to be responsible
for reduced biliary fluidity and alkalinity, and for subse-
quent bile duct damage by cytotoxic compounds [5–7].
Because the antioxidant status in CF patients is compro-
mised and the liver is important in antagonizing oxidative
stress [8], defective metabolism of oxidant and reactive
electrophilic compounds may result in liver damage. The
susceptibility of certain CF patients to oxidative damage
raises the possibility that dysfunctional CFTR may consti-
tutively alter hepatic pathways mediating oxidative and
reactive electrophile metabolism allowing for increased livers 6 (2007) 23 – 30ed by Elsevier B.V. All rights reserved.
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function results in these abnormalities have not been
elucidated.
Cytosolic SULT1E1 (estrogen sulfotransferase) catalyzes
the sulfonation of estrogens that is the major route of h-
estradiol (E2) metabolism at physiological concentrations
[9,10]. E2-sulfate does not activate the estrogen receptors
(ER) and limits the initiation of subsequent transcriptional
effects [11]. Previous studies have demonstrated that
SULT1E1 is significantly elevated in CFTR-DF508 (/)
mice that survive to adulthood [12]. Therefore, altered
SULT1E1 activity that affects hepatic E2 levels may lead to
changes in E2-responsive proteins at both transcriptional
and post-transcriptional levels, thereby contributing to
pathways intensifying CF-related liver disease.
In the present study, the effect of the loss of CFTR
function on SULT1E1 expression in CFTR-knockout (KO)
mice was determined to be similar to that in CFTR-DF508
mice [12]. An increase in the conjugation of E2 in the livers
of CFTR (/) mice is shown to result in alterations in the
expression of estrogen receptor a and estrogen-regulated
genes. Changes in expression of selected hepatic genes in
mice with both CFTR-KO and DF508 (/) genotypes
provide insights into possible mechanisms of liver patho-
genesis and dysfunction in CF.2. Materials and methods
2.1. Materials
E2 and DNA polymerase were obtained from Sigma (St.
Louis, MO). [32P]dCTP (3000 Ci/mmol) and [3H]E2 (56 Ci/
mmol) were purchased from DuPont–NEN (Boston, MA).
3V-Phosphoadenosine 5V-phosphosulphate (PAPS) was
from Dr. Sanford Singer (University of Dayton, Dayton,
OH). RNA STAT-60 was purchased from Tel-Test (Friends-
wood, TX). Quickhyb was obtained from Stratagene (La
Jolla, CA). Rabbit anti-ERa and anti-ERh polyclonal
antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Superscripti C RNase H-reverse tran-
scriptase was purchased from Invitrogen (Carlsbad, CA).
2.2. Mice
CFTR-KO mice are the North Carolina strain (B6.129P2-
Cftrtm1Unc) in which exon 10 is disrupted and CFTR
protein is not synthesized [13]. CFTR-DF508 mice
(B6.129S6-Cftrtm1Kth, Jackson Laboratory, Bar harbor,
ME) carry a deletion of Phe508 disrupting the proper
intracellular transport of the mutant CFTR protein. Mice
were housed in the University of Alabama at Birmingham
(UAB) Cystic Fibrosis Research Center animal care facility
and all experimental protocols were approved by the UAB
Institutional Animal Care and Use Committee. The homo-
zygous CFTR-KO and DF508 (/) mice were obtained bymating heterozygous (+/) mice. Mice were maintained on
a liquid diet after weaning and genotypes were determined
by PCR as described previously [12,14]. After 9 weeks of
age, the mice were sacrificed, and the livers excised,
weighed and stored at 80 -C until analysis.
2.3. Laser capture microdissection (LCM)
LCM was used to isolate pure populations of hepatocytes
from the livers of wild type C57BL/6 mice. Livers were
removed and frozen in O.C.T tissue-freezing media. Frozen
sections (8 Am) were cut and rapidly stained with
hematoxylin and eosin for visualization of target cells.
Aliquots of approximately 2000 hepatocytes were micro-
dissected using a Pixell II Laser Capture Microdissection
System (Arcturus Engineering, Mountain View, CA).
2.4. Cell culture
Human HepG2 hepatocytes (ATCC, Rockville, MD) and
human MMNK-1 cholangiocytes (a gift from Dr. Kobaya-
shi, Okayama University, Japan) were maintained in
modified-MEM and DMEM, respectively, supplemented
with 10% fetal bovine serum, 1% non-essential amino acids
and sodium pyruvate in a humidified incubator with 5%
CO2 at 37 -C.
2.5. RT-PCR analysis
Total RNA from microdissected hepatocytes was isolated
using a RNAqueous-Micro Kit (Ambion, Austin, TX) and
from HepG2 and MMNK-1 cells using STAT-60. Total
RNA was used for first-strand cDNA synthesis with
Superscript C RNase H-reverse transcriptase and random
primers. SULT1E1 and CFTR messages were determined by
PCR analysis using specific primers (Table 1).
2.6. Liver cytosolic SULT1E1 activities
To prepare liver cytosols, 100 mg of each frozen mouse
liver was homogenized on ice in 5 vol of 10 mM
phosphate buffer, pH 7.4, containing 1 mM dithiothreitol
and 10% glycerol. Liver homogenates were centrifuged at
100,000 g for 1 h. Protein concentrations were estimated
using the Bio-Rad protein assay. SULT1E1 activity was
determined using 20 nM [3H]E2 as substrate and 10 AM
PAPS as the sulfate donor as described previously [15].
2.7. Northern-blot analysis
The mouse SULT1E1 cDNA probe was generated by
PCR using oligonucleotide primers (Table 1) to generate a
867 bp product [16]. The 867 bp PCR product was
radiolabelled with [32P]dCTP using the Prime-It Random
Priming Kit (Promega, Madison, WI). Total RNA (20 Ag)
from each liver was resolved by formaldehyde–agarose gel
Table 1
Sequences of oligonucleotides
Primer sequence Expected
products
Human SULT1E1
(5VY3V)
430 bp
Forward TATTGCCACCTACCCTAAATCTG
Reverse CTCTTTCCCTTTTCCCACCAAG
Human CFTR
(5VY3V)
332 bp
Forward ACTTCACTTCTAATGATGAT
Reverse AAAACATCTAGGTATCCAA
Mouse SULT1E1
(5VY3V)
314 bp
Forward TCCGTGGAGTTCTAATGGACAAAC
Reverse CCA AAATGATGCTGGAAGGACC
Mouse CFTR
(5VY3V)
160 bp
Forward ACTATCAAAGAAAATATCATCTT
Reverse TCACAACACTGACACAAGTAGC
Mouse SULT1E1
(5VY3V, for probe)
867 bp
Forward TCCGTGGAGTTCTAATGGACAAAC
Reverse ATTTCAGACACAAGGAAGTGGCTC
Fig. 1. SULT1E1 and CFTR expression in mouse hepatocytes, human
HepG2 hepatocytes and human MMNK-1 cholangiocytes. Panel A) Pure
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linked and probed with [32P]dCTP labeled SULT1E1 probe.
The blot was washed twice (15 min each time) at room
temperature in low stringency wash buffer (2 SSC and
0.1% SDS), and then twice (15 min each time) at 68 -C in
high stringency wash buffer (0.1 SSC and 0.1% SDS) and
visualized by autoradiography.
2.8. Immunoblot analysis
To analyze ERa and ERh expression, 100 Ag cytosolic
protein was resolved by SDS-PAGE and transferred to
nitrocellulose membranes. Immunoblot analysis was per-
formed as described previously [17], with primary antibody
(1/500 dilution) incubations at 4 -C overnight and second-
ary anti-HRP conjugated antibody incubation at RT for 1 h.
Visualization of bound proteins was carried out using the
Supersignal West Pico System (Pierce, Rockford, IL) and
autoradiography. All blots were performed three times. The
bands were analyzed by imaging densitometry as described
previously [18], and protein levels were evaluated by
comparison to the levels in control CFTR (+/+) mice.populations of hepatocytes were isolated by laser capture microdissection
from frozen sections of normal C57BL/6 mouse liver. Total RNA was
isolated and RT-PCR was performed using SULT1E1 and CFTR specific
primers (Table 1). Lane 1 contains DNA markers. Products generated by
PCR using SULT1E1 specific primers are in lanes 2 and 4. Products
generated by PCR using CFTR specific primers are in lanes 3 and 5. Mouse
genomic DNA was used as positive controls for SULT1E1 and CFTR
amplification in lanes 4 and 5, respectively. Panel B) cDNAs generated by
reverse transcription of total RNA from HepG2 and MMNK-1 cells were
used as PCR templates in lanes 2 and 3, and lanes 4 and 5, respectively.
PCR products generated with SULT1E1 specific primers are shown in lanes
2, 4 and 6. Products amplified with CFTR specific primers are in lanes 3, 5
and 7. SULT1E1 and CFTR containing plasmids are used as PCR positive
controls in lanes 6 and 7, respectively.3. Results
3.1. Differential expression of SULT1E1 and CFTR in
hepatocytes and cholangiocytes
Human and mouse liver cytosols have been demonstrated
to contain SULT1E1 [9,10]. CFTR is expressed in biliary
epithelial cells where it is involved with the generation of
bile secretion [19,20]. Whether CFTR is also expressed in
hepatocytes remains unclear. Pure populations of hepato-cytes were isolated from mouse liver by LCM, however,
sufficient numbers of cholangiocytes could not be isolated
from cross-sections of mouse liver tissue for LCM analysis.
CFTR and SULT1E1 expression was analyzed in the pure
populations of mouse hepatocytes by RT-PCR. Fig. 1A
shows the generation of SULT1E1 specific product from
mouse hepatocyte total RNA. In contrast, no CFTR specific
products were detected in mouse hepatocyte total RNA (Fig.
1A). Similar RT-PCR results were observed using total
RNA from human HepG2 hepatocytes (Fig. 1B) indicating
that SULT1E1 message, but not CFTR message, was
detectable in both mouse and human hepatocytes. CFTR
message, but not SULT1E1 message, was amplified from
total RNA isolated from human MMNK-1 cholangiocytes
(Fig. 1B).
3.2. Liver cytosolic SULT1E1 activity
Our laboratory has previously reported that SULT1E1
activity is significantly elevated in CFTR-DF508 (/)
mice [12]. To determine whether the induction of SULT1E1
is specific to the CFTR-DF508 mice, CFTR-KO mice were
investigated. CFTR-KO mice do not express CFTR whereas
CFTR-DF508 mice express a dysfunctional protein.
SULT1E1 activity was assayed in liver cytosols from the
three genotypes of CFTR-KO mice. SULT1E1 activity was
significantly increased in several CFTR-KO (/) mouse
liver cytosols as compared with CFTR-KO (+/+) and (+/)
littermates (Fig. 2).
Fig. 2. Sulfation of E2 by mouse liver cytosol from CFTR-KO mice.
SULT1E1 activity was assayed with 20 nM E2 and expressed as picomole
E2 sulfated per milligram cytosolic protein per minute. Because of the
variability of SULT1E1 activities in mice, results are presented as a scatter
graph. Each dot represents an individual mouse.
Fig. 3. Northern-blot analysis of hepatic SULT1E1 message levels in
CFTR-KO mice. Panel A) Northern blot analysis was done to analyze
SULT1E1 mRNA levels in representative CFTR (+/+) and (/) mice.
Corresponding SULT1E1 activities (pmol E2 sulfated/min/mg protein) of
each sample are indicated. Panel B) Ethidium-bromide stained gel of total
RNA prior to transfer to the membrane.
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To confirm that the elevation of E2 sulfation activity in
the CFTR-KO mice was associated with increased
SULT1E1 expression, Northern blot analysis of SULT1E1
expression in the CFTR-KO mouse livers was carried out.
Fig. 3 shows that SULT1E1 message was elevated in liver
RNA of mice with increased cytosolic SULT1E1 activity.
SULT1E1 mRNA was not detectable in mice with cytosolic
SULT1E1 activities below 2 pmol/min/mg protein. Also,
SULT1E1 mRNA levels in a particular CFTR-KO mouse
correlated with the level of SULT1E1 activity, affirming that
the high SULT1E1 activity levels found in livers of CFTR-
KO mice was associated with increased expression of
SULT1E1, similar to the results observed in CFTR-DF508
mice [12].
3.4. SULT1E1 and estrogen receptor levels
Estrogen receptor expression is regulated by several
mechanisms including the levels of estrogens [21]. Since E2
is the major high affinity substrate of SULT1E1 and most of
the genomic effects of E2 involve activation of either ERa
or ERh, the effect of increased SULT1E1 activity on ERa
and ERh expression in the livers of the mice was
investigated. Immunoblot analysis showed that ERa protein
levels were significantly lower in liver cytosols of both
CFTR-KO and DF508 (/) mice with elevated SULT1E1
activities as compared to (+/+) and (+/) mice (Fig. 4).
Unlike ERa, ERh expression was not significantly altered
in either CFTR-KO or DF508 (/) mice regardless of the
SULT1E1 activity levels (Fig. 5). These results indicate that
ERa and ERh are differently affected by the apparent loss
of free E2 in the liver due to increased SULT1E1 activityand that processes regulated by the ERs may be significantly
affected.
3.5. Inhibition of CA-III and GST-P1 in CFTR-KO and
DF508 mice
E2 is involved with the regulation of expression of
numerous proteins via activation of the ERs as well as by
nongenomic mechanisms [22]. Because SULT1E1 activity
directly affects free E2 levels at physiological concen-
trations [11,23,24], the increase in SULT1E1 activity in
CFTR-KO and DF508 mice might result in altered
expression of E2-regulated proteins. Initial studies in-
volved the investigation of changes in the levels of pro-
teins by SDS-PAGE. Fig. 6 showed that the levels of
several proteins differed in both CFTR-KO and DF508
mice as compared to control mice. Two proteins of
approximately 30 Kd and 25 Kd showed a significant
difference in both CFTR-KO and DF508 (/) mice as
compared to control mice. These proteins were sufficient-
ly resolved by SDS-PAGE to be isolated and identified as
carbonic anhydrase III (CA) and glutathione-S-transferase-
P1 (GST-P1), respectively, by limited proteolysis and
MALDI mass spectrometry. CA-III expression was
reduced in both male and female CFTR-KO and DF508
(/) mice, with no apparent differences between
genders. In contrast, the decrease in GST-P1 expression
was more apparent in both CFTR-KO and DF508 (/)
male mice than in females. This is likely related to the
10–20 fold higher expression of GST-P1 in normal male
mice than in female mice [25].
Fig. 4. Reduction of ERa expression in mice with elevated SULT1E1 activity. Immunoblot analysis of different CFTR genotype mice was performed with a
rabbit anti-ERa antibody. Panels A and C show the results of CFTR-KO mice. Panels B and D show the results of CFTR-DF508 mice. Panels C and D show
results of densitometric analysis of autoradiography from experiments performed to quantify ERa levels. The ERa levels in wild-type mice are arbitrarily set to
1 and the data are expressed as meanTS.E. Results are representative of three experiments. The correlation coefficient for the comparison of SULT1E1 activity
and ER-a band intensity is 0.96 in the CFTR-KO mice and 0.97 in the CFTR DF508 mice.
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The hepatic cytochrome P450 (CYP) system is one of the
most important cellular defense systems against toxic
compounds. Several sex-specific P450 isoforms, especiallyFig. 5. ERh levels in mice having different SULT1E1 activities and CFTR
genotypes. Liver cytosolic proteins were resolved by SDS-PAGE and
immunoblotted with a rabbit anti-ERh antibody. Panels A and B show the
results with CFTR-KO and DF508 mice, respectively. Changes in
SULT1E1 activities in the livers of CFTR-KO and DF508 mice did not
alter the expression of ERh. The data shown are representative of three
similar experiments.those of the CYP2B subfamily, are regulated by gonadal
steroids [26,27]. Because of its role in detoxification and
modulation by E2, CYP2B9 mRNA expression in CFTR-
DF508 male mice was examined. Levels of hepatic
CYP2B9 mRNA varied in the CFTR-DF508 (/) male
mice in a manner that correlated with SULT1E1 expression
(Fig. 7). Male mice with the highest SULT1E1 activity had
the highest CYP2B9 mRNA expression levels. In contrast,
CYP2B9 mRNAwas barely detectable in control male mice
that possessed low levels of SULT1E1 activity. In female
CFTR-DF508 mice, CYP2B9 mRNA levels that did not
vary regardless of the liver cytosolic SULT1E1 activity
(data not shown). These results suggest a gender difference
in the role of E2 in the regulation of CYP2B9 expression in
mice.4. Discussion
Although for many years CF was considered a childhood
disease because of its high rate of mortality, current
diagnostic techniques and therapies have lengthened the
life expectancy of patients, many whom survive into
adulthood. Thus, the recognition that CF-associated liver
disease is a problem in the adult CF population has
increased in recent years [4]. The cumulative incidence of
liver disease in adult CF patients is about 17–25% and
hepatic steatosis and focal biliary cirrhosis are observed in
60–70% of CF patients at autopsy [28]. The mechanisms by
Fig. 6. Alteration of CA-III and GST-P1 levels in CFTR mouse liver cytosols. Liver cytosols from CFTR (+/+) and (/) mice (200 Ag) were resolved on a
12% SDS-PAGE gel. The gel was stained with Coomassie blue. Selected protein bands were excised for MALDI mass spectrometric analysis and determined
to be CA-III and GST-P1 as indicated. Lanes 1–4 are from CFTR-KO mice. Lanes 5–8 are from CFTR-DF508 mice. Liver SULT1E1 activities (pmol/min/mg
protein) are 13.7, 0.3, 18.8, 1.4, 36.7, 0.5, 43.8 and 0.1 in lanes 1–8, respectively.
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poorly understood [5,25,28]. The variable onset and severity
of liver disease suggest that other modifying genetic or
environmental factors determine whether clinically signifi-
cant liver disease will occur [29,30]. In the current studies
9–10 week old mice were used and gross histopathologic
liver disease or changes in the plasma indicative of liver
dysfunction were not observed in the CFTR (/) mice.Fig. 7. Northern blot analysis of CYP 2B9 expression in CFTR-DF508 (/)
male mice. Total RNAwas isolated fromCFTRmouse livers and analyzed by
a Northern blot protocol with a 32P-labeled CYP2B9 cDNA probe. Panel A is
the Northern blot of a cross-section of CFTR-DF508 mice with varying
SULT1E1 (EST) activities. Lanes 1 and 2 contain RNA from DF508 (+/+)
genotypemice; lanes 3 and 4,DF508 (+/) mice; lanes 5 to 12,DF508 (/)
mice. Corresponding E2 sulfation activity levels (pmol/min/mg protein) for
each lane are noted in panel A. The correlation coefficient for the comparison
of SULT1E1 activity and CYP2B9message band intensity is 0.97. Panel B is
a picture of the ethidium-bromide stained gel prior to transfer to the
nitrocellulose membrane.However, Durie et al. [31] have reported that in C57BL/6J
CFTR (/) KO mice all the animals show progressive
liver disease with age. These authors report fibrotic changes
in 3 month old animals, and biliary and lobular cirrhosis and
steatosis in animals over 12 months in age.
Our laboratory has previously reported that SULT1E1
activity was significantly elevated in livers of CFTR-DF508
(/) mice [12]. In CFTR-DF508 (/) mice that survive
to adulthood SULT1E1 was highly and selectively induced
in the livers of all female and half of the male mice. In the
present study similar increases in SULT1E1 expression were
also observed in CFTR-KO mice that lack expression of
CFTR protein. CFTR is expressed in both the intrahepatic
and extrahepatic biliary epithelial cells in normal human
liver, although CFTR is not detected immunohistochemi-
cally in hepatocytes [19]. Consistent with this observation,
CFTR message was not detected by RT-PCR in total RNA
from mouse hepatocytes (Fig. 1). Since SULT1E1 is
expressed in hepatocytes, the loss of CFTR function in
cholangiocytes is capable of eliciting induction of SULT1E1
expression in hepatocytes. The mechanism by which the
CFTR (/) cholangiocytes elicit the induction of
SULT1E1 expression in hepatocytes is not known.
Because of its high affinity for E2, an increase in liver
SULT1E1 activity is expected to decrease the levels of
active E2 in hepatocytes. A reduction in active E2 levels
may thereby alter the levels of estrogen-regulated proteins
resulting in many downstream effects. Thus, elevated
SULT1E1 activity may regulate expression of E2-regulated
liver proteins and thereby may have an effect in the
progression of the CF-associated liver disease. Many of
the actions of estrogens are mediated through ERa and ERh
L. Li, C.N. Falany / Journal of Cystic Fibrosis 6 (2007) 23–30 29that function as ligand-activated transcription factors in
target cells [32]. Decreased levels of ERa, but not ERh,
were demonstrated in both CFTR-KO and DF508 (/)
mice with elevated SULT1E1 activity. The strong correla-
tion of low ERa expression with high SULT1E1 activity
indicates that reduced ERa levels may be the result of a
decrease in free E2 levels. Increasing levels of SULT1E1
activity in human MCF-7 breast cancer cells is also
associated with decreased expression of ERa [24]. The
decrease in ERa expression provides a mechanism for
alterations in expression of many proteins or processes
regulated by estrogens in hepatocytes.
Two of the readily detectable changes in E2 regulated
proteins in both CFTR-KO and DF508 (/) mice involved
CA and GST-P1. CA, a membrane protein involved in
HCO3
 secretion, was significantly reduced in CFTR-KO
and DF508 (/) mice of both sexes whereas GST-P1, a
protein constitutively expressed at high levels in male mice,
was dramatically decreased in male CFTR (/) mice with
high SULT1E1 activities only. Both CA and GST-P1 are
estrogen-responsive proteins that play important roles in
defense against oxidative stress and toxic compounds
involved in aging and the pathogenesis of many diseases
[33,34]. In pancreatic duct cells which express CFTR-
DF508, the intracellular trafficking of CA is impaired [35],
and E2 modulates CA expression in male mouse efferent
renal ductules via ERa [36]. GST-P1 is involved in
detoxification reactions and also has a protective role
against oxidative stress. Glutathione deficiency plays a role
in aging and the pathogenesis of many diseases including
CF [37]. These factors support the possibility that E2 is a
critical factor in regulating the expression of key ion
transporters and detoxication enzymes, and supports the
idea that decreased E2 activity is involved with CF liver
disease.
CYP450 is important in the metabolism of drugs and
xenobiotics in the liver as well as in the generation of
reactive oxygen species (ROS) and reactive electrophilic
compounds [38]. CYP2B9 is a major CYP in mouse liver
and its expression is regulated by estrogens [27]. CYP2B9
expression was increased only in liver of male CFTR-
DF508 (/) mice with high SULT1E1 activity (Fig. 7). In
contrast, CYP2B9 expression is reportedly induced by E2 in
male C57BL/6 mice [39] and induced by testosterone in
DBA/2 and Balb/c mice [27]. These results suggest that the
increases in E2 sulfation may interact with other regulatory
factors in liver to modulate CYP450 protein expression.
The alterations in ERa, CA-IC, GST-P1 and CYP2B9
expression suggest a mechanism that may result in an
increase in oxidative stress and electrophilic damage in
hepatocytes of CFTR (/) mice. The mechanism for the
alteration of E2-responsive proteins in CFTR (/) mice
may be through ER-mediated signaling which is important
and necessary for multiple cellular processes [40,41]. ERa-
mediated signaling pathways are modulated by E2 levels
that are in turn decreased by increased SULT1E1 activity.Large increases in CYP activity would result in increased
ROS and reactive electrophile generation whereas decreases
in GST activity would remove an important protective
mechanism. These results indicate that loss of functional
CFTR in biliary epithelial cells can cause a series of
dysfunctional changes in the liver that may contribute to the
onset or pathology of liver disease. Physiologically, we
speculate that at some point in CFTR (/) mice an
increase in liver SULT1E1 activity is induced and the levels
of free E2 in the liver are decreased, resulting in alterations
in the expression of E2-regulated proteins.Acknowledgements
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